Literature DB >> 20155339

A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance.

Yoshiko Nakagawa1, Katsuhiro Miura, Tetsuo Yamazaki, Hikaru Ishizuka, Kazuhiro Takei, Umihiko Sawada, Yoshimasa Kura, Yoshihiro Hatta, Jin Takeuchi.   

Abstract

Although great advancements have been witnessed in treatment results for hematopoietic tumors in recent years, development of secondary malignant tumors induced by anti-cancer drugs still remains a serious issue. We experienced a case of secondary myelodysplastic syndrome (MDS), possibly induced by cyclophosphamide (CY), which was spontaneously resolved by discontinuance of CY. A 24-year-old woman was diagnosed with follicular lymphoma in January 1998: she had developed bulky intra-abdominal lymphadenopathy, with repeated relapse and remission by several chemotherapy treatments. Remission was induced by rituximab, administered at the time of relapse in 2001, followed by administration of 50 mg/day of CY since December 2001 for the prevention of relapse. Anemia and thrombocytopenia developed around January 2003. Bone marrow aspiration revealed abnormality in two lineages and a complicated chromosomal anomaly, and the patient was diagnosed with MDS. Discontinuance of CY and administration of an anabolic steroid improved anemia and thrombocytopenia within 2 years. Bone marrow aspiration in 2006 showed improvement in morphological abnormality and disappearance of chromosomal abnormality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155339     DOI: 10.1007/s12185-010-0511-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

Review 1.  Therapy related leukemias: susceptibility, prevention and treatment.

Authors:  G Leone; M T Voso; S Sica; R Morosetti; L Pagano
Journal:  Leuk Lymphoma       Date:  2001-04

2.  Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.

Authors:  Georg Lenz; Martin Dreyling; Eva Schiegnitz; Torsten Haferlach; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

Review 3.  Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.

Authors:  K Seiter; E J Feldman; C Sreekantaiah; M Pozzuoli; J Weisberger; D Liu; C Papageorgio; M Weiss; R Kancherla; T Ahmed
Journal:  Leukemia       Date:  2001-06       Impact factor: 11.528

4.  Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome.

Authors:  S Vadhan-Raj; H E Broxmeyer; G Spitzer; A LeMaistre; S Hultman; G Ventura; J D Tigaud; M A Cork; J M Trujillo; J U Gutterman
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

5.  Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome.

Authors:  Mitsuru Itoh; Kazuhiro Yago; Hideto Shimada; Kaoru Tohyama
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

6.  Repetitious appearance and disappearance of different kinds of clonal cytogenetic abnormalities after allogeneic bone marrow transplantation.

Authors:  Y W Lin; K Hamahata; K Watanabe; S Adachi; Y Akiyama; M Kubota; T Nakahata
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

7.  Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  Jens Pedersen-Bjergaard; Mette K Andersen; Debes H Christiansen; Claus Nerlov
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

Review 8.  Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment.

Authors:  F E van Leeuwen
Journal:  Baillieres Clin Haematol       Date:  1996-03

9.  Spontaneous remission in a patient with therapy-related myelodysplastic syndrome (t-MDS) with monosomy 7.

Authors:  B Renneboog; V Hansen; P Heimann; A De Mulder; F Jannsen; A Ferster
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

10.  Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients.

Authors:  Dragomir Marisavljević; Zoran Rolović; Milena Ludoski-Pantić; Vesna Djordjević; Angelina Novak
Journal:  Med Oncol       Date:  2005       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.